An Analysis of the SWOG S0500 Study
Robert McCormack, PhD, head, Technology Innovation, Janssen Diagnostics, LLC, discusses the SWOG S0500 study, which evaluated different treatments in patients with metastatic breast cancer who had elevated circulating tumor cell (CTC) levels.
Robert McCormack, PhD, head, Technology Innovation, Janssen Diagnostics, LLC, discusses the SWOG S0500 study, which evaluated different treatments in patients with metastatic breast cancer who had elevated circulating tumor cell (CTC) levels.
Clinical Pearls:
- The trial had three arms and enrolled patients with metastatic breast cancer that were about to start first-line chemotherapy treatment
- The patients were given a screening CTC test with CellSearch prior to the start of their treatment
- Patients with less than 5 CTCs were put in arm A while patients with more than 5 CTCs received their chemotherapy treatment for three weeks before receiving another CTC test
- The patients whose CTC levels dropped after three weeks were placed in arm B while the patients whose CTC levels did not drop after three weeks were placed in arm C
- Patients in arm C were either randomized to continue their current treatment or were switched to the next line of chemotherapy
- Results showed that after three weeks of therapy, a survival benefit can be determined based on CTC levels
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
July 24th 2024During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Dato-DXd Shows Promise as a More Tolerable ADC in HER2-Negative mBC
July 22nd 2024During a Case-Based Roundtable® event, Igor Makhlin, MD, discussed with participants their impressions of datopotamab deruxtecan as therapy for patients with HR-positive, HER2-negative breast cancer, and the sequential use of multiple antibody-drug conjugates.
Read More
